Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT01258608 Completed - Clinical trials for Carcinoma, Hepatocellular

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Start date: February 8, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Mapatumumab is a fully human, agonist monoclonal antibody that activates the cell death pathway in tumor cells by specifically binding to TRAIL-R1 with high affinity. Sorafenib, a multikinase inhibitor, is the standard of care for treatment of patients with advanced hepatocellular carcinoma (HCC). The mechanisms of sorafenib and mapatumumab action suggest that these agents could interact synergistically. This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mapatumumab in combination with sorafenib in subjects with advanced hepatocellular carcinoma.

NCT ID: NCT01251458 Completed - Inoperable HCC Clinical Trials

Hepatocellular Carcinoma (HCC)_Torisel_

Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel

NCT ID: NCT01247298 Completed - Clinical trials for Hepatocellular Carcinoma (HCC)

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

RAD 0902
Start date: October 2010
Phase: Phase 0
Study type: Interventional

This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.

NCT ID: NCT01246986 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Start date: March 30, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.

NCT ID: NCT01237132 Completed - Clinical trials for Carcinoma, Hepatocellular

East-West Hepatocellular Carcinoma Study Group

Start date: n/a
Phase: N/A
Study type: Observational

The current treatment guidelines of hepatocellular carcinoma (HCC) of the American and European Associations for the Study of Liver Disease are based on the Barcelona-Clinic-Liver-Cancer classification (BCLC), which does not recommend surgery in patients with large, multinodular and macrovascular invasive disease. The aim of this study was to investigate the role of hepatic resection in a large retrospective multicentric cohort of patients resected for HCC regardless of the BCLC indications.

NCT ID: NCT01232296 Completed - Clinical trials for Hepatocellular Carcinoma

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of this open-label, randomized, phase II study is to compare the safety and efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with advanced Hepatocellular Carcinoma (HCC). This trial will be opened in countries of the Asia-Pacific region.

NCT ID: NCT01229839 Completed - Clinical trials for Hepatocellular Carcinoma

Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC

Start date: August 2013
Phase: Phase 3
Study type: Interventional

TACE is considered the standard treatment for unresectable HCC on the basis of the fact that there are no alternative to curative procedures.But the optimal combined regimen is still unclear. One of the controversy is do the protocol should contain lipiodo and how to executer. The investigators hypothesize that TACE without mixing the chemotherapy with lipiodol is not unacceptably worse than TACE mixing the chemotherapy with lipiodol.

NCT ID: NCT01213758 Completed - Clinical trials for Hepatocellular Carcinoma

Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

Start date: June 2010
Phase: N/A
Study type: Observational

Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.

NCT ID: NCT01210495 Completed - Clinical trials for Hepatocellular Carcinoma

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Start date: December 6, 2010
Phase: Phase 2
Study type: Interventional

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

NCT ID: NCT01204177 Completed - Clinical trials for Carcinoma, Hepatocellular

Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

BASIL
Start date: December 2010
Phase: Phase 2
Study type: Interventional

This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer. Safety will be determined by laboratory and other evaluations. Efficacy of the combination BAY86-9766 and sorafenib will be determined by disease control rate, overall survival, time to progression, response rate and duration of response.